Riociguat - Bayer

Drug Profile

Riociguat - Bayer

Alternative Names: Adempas; BAY-32521; BAY-63-2521

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Class 2 ring heterocyclic compounds; Carbamates; Fluorobenzenes; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase II Cystic fibrosis; Raynaud's disease; Systemic scleroderma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 Apr 2018 Merck has patent protection for riociguat in USA, Europe and Japan
  • 10 Oct 2017 Bayer terminates phase II trial in Cystic fibrosis in USA, Canada, Germany, the Netherlands, United Kingdom, Belgium, France, Greece and Italy, based on multiple factors, including the design of part 2 is no longer appropriate (NCT02170025)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top